Expert Consensus on Off-label Use of Bevacizumab

Angiogenesis is an extremely complex biological process, which plays an important role in the growth and metastasis of various tumors, besides, the significant increase of anti-vascular endothelial growth factor is closely related to the pathogenesis and development of retinal vascular disease. Bevacizumab is the first angiogenesis inhibitor approved for first-line treatment of advanced non-small cell lung cancer. Some clinical trials, systematic reviews and meta-analysis have found that bevacizumab has therapeutic effects in indications other than those currently approved by the National Medical Products Administration. All indications of bevacizumab were gathered by querying the latest edition of bevacizumab instructions, authoritative guidelines and diagnosis and treatment specifications on domestic and foreign websites. The off-label drug use research literature of bevacizumab in the treatment of various cancers was collected by searching in PubMed, CNKI, Wanfang Database from the establishment of the database to December 2022. The expert consensus on off-label drug use of bevacizumab was finally formed in order to provide reference for clinical medication.